A macro–micro–macro radiogenomic framework identifies FIBCD1 as a key immune-modulating biomarker in breast cancer
Our findings establish a novel radiogenomic strategy that bridges MRI-derived imaging phenotypes with molecular mechanisms. FIBCD1 may serve as an immune-modulating prognostic biomarker linked to imaging characteristics, providing new insights into non-invasive breast cancer risk assessment and therapeutic targeting.
Authors
- Bing Zhou (ORCID: https://orcid.org/0000-0002-7568-8175)
- Wenjing Jiang (ORCID: https://orcid.org/0000-0002-1559-9744)
- Minping Hong
- Zhenyi Ma (ORCID: https://orcid.org/0000-0001-6962-2711)
- Jie Hou (ORCID: https://orcid.org/0000-0003-2349-9230)
- Haitao Sun (ORCID: https://orcid.org/0000-0003-4734-9683)
- Xiaobo Chen (ORCID: https://orcid.org/0000-0001-8755-6199)
- Xiaowen Huang (ORCID: https://orcid.org/0000-0002-2671-1682)
- Keng Ling (ORCID: https://orcid.org/0000-0003-0081-5069)
- Jie He
- Yujie Ying
Institutions
- Zhejiang Chinese Medical University (CN)
- Shanghai Medical College of Fudan University (CN)
- Fudan University (CN)
- Sir Run Run Shaw Hospital (CN)
- Jiaxing University (CN)
- Key Laboratory of Guangdong Province (CN)
- Zhongshan Hospital (CN)
- Zhejiang Provincial People's Hospital (CN)
- First Hospital of Jiaxing (CN)
- Guangdong Academy of Medical Sciences (CN)
- Guangdong Provincial People's Hospital (CN)
- Hangzhou Medical College (CN)
- Southern Medical University (CN)
- Zhejiang University (CN)
Publication Details
- Journal
- Journal of Translational Medicine
- Published
- 2025-11-25
- DOI
- https://doi.org/10.1186/s12967-025-07389-z
- Primary Topic
- Ferroptosis and cancer prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00